These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 9606450

  • 1. Reducing expenditures for statin-type lipid-lowering agents.
    Am J Health Syst Pharm; 1998 May 15; 55(10):995-6, 999. PubMed ID: 9606450
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Managed care trends in statin usage.
    Bazalo GR.
    Manag Care; 2001 Oct 15; 10(10):48-50, 53-9. PubMed ID: 11688111
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of low-density-lipoprotein lowering with statins.
    Leufkens HG, Herings RM, Urquhart J.
    Lancet; 1994 Sep 03; 344(8923):683-4. PubMed ID: 7915368
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of low-density-lipoprotein lowering with statins.
    Seidel D, Cremer P.
    Lancet; 1994 Sep 03; 344(8923):683. PubMed ID: 7915367
    [No Abstract] [Full Text] [Related]

  • 8. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
    Perreault S, Hamilton VH, Lavoie F, Grover S.
    Arch Intern Med; 1998 Feb 23; 158(4):375-81. PubMed ID: 9487235
    [Abstract] [Full Text] [Related]

  • 9. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR.
    Clin Cardiol; 1995 Jun 23; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective.
    Benner JS, Smith TW, Klingman D, Tierce JC, Mullins CD, Pethick N, O'Donnell JC.
    Value Health; 2005 Jun 23; 8(6):618-28. PubMed ID: 16283862
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Selection of appropriate type and intensity of lipid-lowering therapy.
    Tikkanen MJ.
    Curr Opin Lipidol; 1995 Dec 23; 6(6):360-4. PubMed ID: 8750248
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden.
    Martikainen JA, Soini E, Paulsson T.
    Curr Med Res Opin; 2010 Feb 23; 26(2):389-96. PubMed ID: 20001451
    [Abstract] [Full Text] [Related]

  • 17. [Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
    Ruiz García A, Gordillo López FJ, Arranz Martínez E, Hermosa Hernán JC.
    Med Clin (Barc); 2011 Jun 25; 137(3):119-25. PubMed ID: 21074814
    [Abstract] [Full Text] [Related]

  • 18. Perspectives on dynamic optimisation and control theory in treating hyperlipidaemia.
    Vernon JA.
    Pharmacoeconomics; 2007 Jun 25; 25(7):533-5. PubMed ID: 17610335
    [No Abstract] [Full Text] [Related]

  • 19. Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.
    Ara R, Rafia R, Ward SE, Wierzbicki AS, Reynolds TM, Rees A, Pandor A.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct 25; 9(5):423-33. PubMed ID: 19817526
    [Abstract] [Full Text] [Related]

  • 20. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD.
    Am Heart J; 1999 May 25; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.